Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 52, Issue 4, Pages 560-566
Publisher
Informa UK Limited
Online
2011-02-22
DOI
10.3109/10428194.2011.552139
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acute Lung Toxicity Related to Pomalidomide
- (2011) Holly L. Geyer et al. CHEST
- International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens
- (2010) Prakash Thapaliya et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- Arterial thrombosis complicates myeloma?
- (2010) M. Q. Lacy BLOOD
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt
- (2010) Elena Mishchenko et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of Transplantation for Myelofibrosis
- (2009) Karen K. Ballen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
- (2009) L. Escoubet-Lozach et al. CANCER RESEARCH
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
- (2008) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
- (2008) Matthew J. Streetly et al. BRITISH JOURNAL OF HAEMATOLOGY
- A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
- (2008) Marie von Lilienfeld-Toal et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
- (2008) Donna E. Reece et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started